CHRU De Nancy
Verified site
Vandoeuvre Les Nancy, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study looks at adults with moderately to severely active Crohn’s disease or ulcerative colitis, two conditions that cause inflammation of the digestive tract and can lead to abdominal pain, diarrhea, and weight loss. The investigational medicines are risankizumab and trosunilimab, which are given together as the combination known as ABBV-466. Each medicine works by blocking parts of the immune system that drive inflammation. Some participants will receive a placebo instead of the active drugs.
The purpose of the study is to see whether the combination works better and is safe compared with each medicine alone. Participants will receive a series of injections or infusions over several weeks. At scheduled visits doctors will ask about symptoms, perform simple stool checks, and use a thin camera (endoscopy) to look inside the intestine. The main goal is to find out how many people have endoscopic remission, meaning the camera shows no visible inflammation after about 28 weeks, while safety is monitored by recording any unwanted effects.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
8 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Vandoeuvre Les Nancy, France
Frankfurt, Germany
Leuven, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a laboratory‑made protein that attaches to a part of the immune system called interleukin‑23. By blocking this signal, it helps reduce the inflammation that causes symptoms of Crohn’s disease and ulcerative colitis. In the study it is given by injection under the skin or into a vein.
is a human‑engineered antibody that targets a molecule called alpha4beta7 integrin. This molecule normally guides immune cells to the lining of the gut. By blocking it, ABBV-382 prevents those immune cells from entering the intestine, which can lower gut inflammation. It is administered as an injection or infusion.
is a combination therapy that includes both risankizumab and trosunilimab, another monoclonal antibody. The two drugs work together: risankizumab blocks the interleukin‑23 pathway, while trosunilimab targets a different part of the immune response. Using them together may give a stronger effect in controlling moderate to severe Crohn’s disease or ulcerative colitis. This combination is also given by injection or infusion.
This medication is given as a solution for injection or infusion, usually by subcutaneous injection. It is an approved drug that is listed in medical references for the treatment of moderate to severe Crohn’s disease, ulcerative colitis, and plaque psoriasis. Risankizumab works by attaching to a protein called interleukin‑23, stopping it from triggering inflammation in the gut. It belongs to the class of monoclonal antibodies known as IL‑23 inhibitors.
The drug is supplied as a solution for injection or infusion and can be administered intravenously or subcutaneously. It is still an investigational product and has not yet received regulatory approval, being studied in clinical trials for inflammatory bowel diseases. It blocks the α4β7 integrin on immune cells, which prevents these cells from moving into the intestine and causing inflammation. This agent is classified as a humanised IgG1 kappa monoclonal antibody that acts as an integrin antagonist.
A chronic inflammatory condition that can affect any part of the gastrointestinal tract, most often the small intestine and colon. It causes swelling and ulceration, leading to abdominal pain, diarrhea, and weight loss. Over time the inflammation may create narrowings (strictures) or abnormal connections (fistulas) between organs. Symptoms tend to appear in cycles, with periods of worsening called flares followed by calmer periods. The inflammation can extend through several layers of the intestinal wall.
A chronic inflammatory disease that is limited to the colon and rectum. It produces ulceration of the inner lining, causing bloody diarrhea, urgency, and abdominal cramps. The condition usually begins in the rectum and can spread continuously upward through the colon. As the disease progresses, a larger portion of the colon may become inflamed, increasing the frequency of symptoms. Like Crohn's disease, it shows cycles of flare and remission.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.